Yamaha Motor: First Exhibition at HANNOVER MESSE 2018, World's Leading Trade Fair for Industrial Technology
Yamaha Motor Co., Ltd. (TOKYO:7272) announced today that it will exhibit for the first time at the HANNOVER MESSE 2018, a B to B industrial technology trade show to be held in Hannover, Germany, from Monday, April 23 to Friday, April 27, 2018. Based on the theme of “Fully-Digitalized Production through Robot Transport,” the Yamaha Motor booth will showcase the overall construction of Fully-Digitalized Production lines, including transport processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180404006414/en/
Advanced Robotics Automation Platform (Photo: Business Wire)
The HANNOVER MESSE is the world's leading industrial trade fair, at which leading-edge industrial technology and products are gathered in one place. (The 2017 event saw exhibits held by approx. 6000 companies attracting around 220,000 visitors). The Yamaha Motor booth at the HANNOVER MESSE will feature the Advanced Robotics Automation Platform, as well as an operation demonstration of the Platform and the YK400XR SCARA robot, showcasing the high-speed capability and precision of Yamaha robotics technology to a broad cross-section of the European market.
|
Overview of HANNOVER MESSE 2018 |
||
| Event Period: | April 23 to 27, 2018 | |
| Venue: | Hannover Exhibition Grounds, Germany | |
| No. of exhibitors: | Approximately 6,000 | |
| No. of Attendees: |
220,000 people* *Previous event (2017) |
|
| Yamaha Motor Exhibit Outline | ||
| Exhibit Space: | Hall17, B06 | |
| Details: |
- Exhibition and demonstrations |
|
Models to be Exhibited by Yamaha Motor
Advanced Robotics Automation Platform
This new robotics system enables automation of complex advanced production facilities rapidly and at low cost. The system enables integrated control in one unit of the multiple robots and peripheral devices necessary for production facilities, reducing wasted time through the full digitalization of facilities.
ARAP Product Website:
https://www.yamaha-motor.co.jp/robot/platform/en/
Explanatory video:
https://youtu.be/r_x_WSFj4rc
YK400XR
This SCARA robot features both high quality/functionality and excellent cost-performance. These robots deliver outstanding high rigidity, high-speed capability, and high-accuracy capability. They are utilized across a wide range of production processes, from production facilities for electrical/electronic components and compact precision machinery parts requiring precision assembly, through to transfer and transport in large automotive component assembly.
YK400XR Product Website:
https://global.yamaha-motor.com/business/robot/lineup/ykxg/
Applications:
https://global.yamaha-motor.com/business/robot/lineup/application/ykxg/
Introduction
of Features:
https://global.yamaha-motor.com/business/robot/lineup/ykxg/small/yk400xr/
Demonstration
video:
https://youtu.be/5b7JbiONZvY
History of Yamaha Motor Industrial Robots
1974: Yamaha Motor
begins research and development into industrial robots in order to
streamline production and increase machining precision in its own
motorcycle factories
1976: SCARA robots introduced to Yamaha Motor
motorcycle production lines
1981: Industrial Robots business
established. External sales begin
1984: SCARA robot sales begin
overseas
2013: Linear conveyor module LCM100 launched
2016:
Advanced Robotics Automation Platform integrated controller (PLC)
launched
2017: New Robotics Business building begins operation
Yamaha Motor’s lineup of industrial robots ranging from industrial robots to controllers, which powerfully support the automation of production sites, is rich in variation. YMC builds on these strengths to pursue greater efficiency and quality in increasingly complex, diverse, and high-speed production sites.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180404006414/en/
Contact information
Yamaha Motor Co., Ltd.
Naoto Horie, +81-3-5220-7211
PR Group
Corporate
Communication Disivion
https://www.mynewsdesk.com/yamaha-motor
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom